{"product_id":"sgry-bcg-matrix","title":"(SGRY) Surgery Partners, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Surgery Partners, Inc. BCG Matrix helps you assess how the company’s business units or services fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e108 ambulatory surgery centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgery Partners, Inc.'s 108 ambulatory surgery centers are the core growth platform in a 126-facility network across 31 states. Same-day surgery keeps shifting outpatient, so demand stays structurally strong. This makes the ASC base a clear Star in the BCG matrix, with scale and operating leverage still expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrthopedics and musculoskeletal surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrthopedics and musculoskeletal surgery is a Star for Surgery Partners, Inc. because joint and spine cases keep shifting to outpatient care; CMS has expanded the ASC-approved procedure list to more than 500 codes. This is one of the fastest-growing ambulatory lines, with total joint replacements already common in ASCs. Surgery Partners, Inc. can scale it by tying in surgeons and packing more cases into dense centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterology and endoscopy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGastroenterology and endoscopy is a Star for Surgery Partners, Inc. because GI care is high-volume and keeps moving out of hospitals; outpatient endoscopy already handles most routine cases, supporting steady ASC utilization. In 2024, Surgery Partners generated $3.1 billion in revenue, and this service line fits its low-cost, repeat-case model. That mix supports recurring flow and strong scheduling density.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnesthesia services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnesthesia services is a Star because it scales with Surgery Partners, Inc.'s surgical case volume and ASC buildout. In 2025, outpatient procedures kept rising, so demand stayed high across both owned centers and affiliated providers. This makes the line a strong cash driver with limited demand risk.\u003c\/p\u003e\n\u003cp\u003eIt also benefits from Surgery Partners, Inc.'s broad network of 200+ facilities, since each added case can pull anesthesia revenue higher. The service is tightly linked to same-day surgery, so more orthopedic, GI, and pain cases mean more utilization. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVolume-linked, high-repeat demand\u003c\/li\u003e\n\u003cli\u003eSupports owned and affiliated sites\u003c\/li\u003e\n\u003cli\u003eRises with outpatient case growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDe novo ASC development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDe novo ASC development is a Star for Surgery Partners, Inc. because each new center can create share in local surgical markets that are still growing. It is also one of the clearest ways capital can turn into long-run scale, since a ramped center adds surgeons, cases, and payer mix over time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew centers seed future market share.\u003c\/li\u003e\n\u003cli\u003eCapital spend can compound into scale.\u003c\/li\u003e\n\u003cli\u003eRamp speed drives the return.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgery Partners’ ASC Network Powers Same-Day Care Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgery Partners, Inc.'s Star assets are its 108 ASCs in a 126-facility, 31-state network, plus orthopedics, GI, anesthesia, and de novo development. These lines ride the shift to same-day care, which lifted 2024 revenue to $3.1 billion and kept utilization high in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar area\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCs\u003c\/td\u003e\n\u003ctd\u003e108 centers\u003c\/td\u003e\n\u003ctd\u003eOutpatient volume growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\u003c\/td\u003e\n\u003ctd\u003e126 facilities, 31 states\u003c\/td\u003e\n\u003ctd\u003eScale and density\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$3.1 billion, 2024\u003c\/td\u003e\n\u003ctd\u003eHigh case flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSurgery Partners’ BCG Matrix maps its service lines into Stars, Cash Cows, Question Marks, and Dogs to guide invest\/hold\/divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Surgery Partners, Inc. BCG Matrix that quickly spots winners and laggards to simplify strategy decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Surgery Partners, Inc. so teams can verify assumptions quickly and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e18 surgical hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgery Partners, Inc. reported 18 dedicated surgical hospitals, a mature asset base that usually throws off steadier cash flow than newer ASCs. These hospitals also help lock in referral patterns in local markets, which supports case volume and pricing power. As a cash cow in the BCG matrix, this segment can fund growth elsewhere while carrying lower ramp-up risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneral surgery is a cash cow for Surgery Partners, Inc. because it is repeatable, high-volume care that keeps operating rooms busy with little service-line reinvention. In 2025, Surgery Partners reported about $3.1 billion in revenue, and that scale is helped by steady, everyday procedures across many markets. This kind of mix fills capacity and supports cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmology is a clear Cash Cow for Surgery Partners, Inc. because cataract and other eye cases are highly standardized, quick to turn, and recur at scale; U.S. cataract surgery tops 4 million procedures a year. That steady volume supports strong operating leverage and dependable cash generation, even if growth is modest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePain management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePain management fits Cash Cows because it is a mature outpatient line with steady demand and lower volatility than newer growth areas. For Surgery Partners, Inc., this kind of procedure mix can support repeat cash flow with relatively modest capital needs, since many cases are short-stay and do not need heavy site build-out. The U.S. outpatient shift stays strong, with ambulatory surgery centers still taking share from higher-cost hospital settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable, repeat procedure demand\u003c\/li\u003e\n\u003cli\u003eLower reinvestment than growth lines\u003c\/li\u003e\n\u003cli\u003eCash flow often stays consistent\u003c\/li\u003e\n\u003cli\u003eLess exposed to fast category swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmbedded ancillary services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmbedded ancillary services at Surgery Partners, Inc.—imaging, pharmacy, lab, physical therapy, and wound care—act like cash cows because they sit inside the existing outpatient site base, so they need little new build-out. In 2025, the model still scales off a large network of 200+ facilities, which keeps utilization high and capex light.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady demand from same-site patients\u003c\/li\u003e\n\u003cli\u003eLow growth spend, strong cash conversion\u003c\/li\u003e\n\u003cli\u003eHigher value per surgical episode\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgery Partners’ Cash Cows: 18 Hospitals Power Steady Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows at Surgery Partners, Inc. are the mature lines that keep cash flowing: 18 dedicated surgical hospitals, general surgery, ophthalmology, pain management, and embedded ancillaries. In 2025, Surgery Partners, Inc. generated about $3.1 billion in revenue, supported by repeat, high-volume outpatient care. These units need less reinvestment than growth bets and help fund expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e18 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e~$3.1B in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\u003c\/td\u003e\n\u003ctd\u003e200+ facilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSurgery Partners, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Surgery Partners, Inc. BCG Matrix document you’ll receive after purchase. The full file is identical to this preview—no hidden sections, no demo content, and no watermarks. It’s ready for immediate use in strategy reviews, presentations, or internal analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObstetrics ancillary care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eObstetrics ancillary care is a Dog for Surgery Partners, Inc. because it is not a core ASC growth engine and needs more labor, room time, and on-call coverage than same-day surgery. It also scales poorly inside an outpatient platform, since obstetrics depends on 24\/7 staffing and higher clinical complexity, not high-turnover procedures. That makes it less attractive than core ASCs, which drove Surgery Partners, Inc. to report 140 facilities and about 50,000 procedures per month in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology ancillary care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology ancillary care is a weak fit for Surgery Partners, Inc.'s outpatient model. It needs deeper clinical infrastructure, multidisciplinary teams, and scale, while most revenue stays tied to complex care pathways, not fast-turn surgery volumes. That makes it a low-share BCG \"Dog\" with limited near-term upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWound care services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWound care services fit Dogs in Surgery Partners, Inc.'s BCG Matrix because demand is real but local, with low scale and modest incremental return. In 2025, wound care remained a small, site-based specialty, while Surgery Partners still leaned on larger, repeatable outpatient volumes in orthopedics and GI.\u003c\/p\u003e\n\u003cp\u003eThe service line usually depends on referral density and clinic-level staffing, so growth is slower than higher-throughput procedures. That makes it useful, but not a major capital priority.\u003c\/p\u003e\n\u003cp\u003eFor Surgery Partners, Inc., the economics point to hold, not heavy expansion: limited scale, narrower margins, and weaker network effects than core surgical lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall non-core physician practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall non-core physician practices fit the Dogs bucket because minority stakes below 50% are hard to defend in fragmented local markets, and they can absorb integration spend without enough revenue lift in 2025. For Surgery Partners, Inc., these assets can also pull management away from larger ASC opportunities that drive more value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMinority control weakens pricing power.\u003c\/li\u003e\n\u003cli\u003eIntegration costs can outrun returns.\u003c\/li\u003e\n\u003cli\u003eManagement time gets tied up fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-density rural sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-density rural sites are a Dog for Surgery Partners, Inc. because thin-population markets cap procedure volume, so fixed costs are spread over fewer cases. That keeps margins under pressure and makes it harder to build durable share leadership versus denser metro markets. In FY2025, the company still depended on scale in higher-volume sites to lift EBITDA, which shows why sparse markets stay weak contributors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow volume limits case growth.\u003c\/li\u003e\n\u003cli\u003eFixed costs weigh on margins.\u003c\/li\u003e\n\u003cli\u003eShare gains are harder to win.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Dogs Still Weigh on Surgery Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Obstetrics ancillary care, oncology ancillary care, wound care, small non-core physician practices, and low-density rural sites stayed Dogs for Surgery Partners, Inc. because they had weaker scale, lower margins, and poorer fit than high-volume ASCs. Surgery Partners, Inc. operated 140 facilities and about 50,000 procedures per month in 2025, so capital still favored dense outpatient volumes. These lines are best held, trimmed, or left to run off.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eWhy weak\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eObstetrics\u003c\/td\u003e\n\u003ctd\u003e24\/7 staffing\u003c\/td\u003e\n\u003ctd\u003eLow ASC fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRural sites\u003c\/td\u003e\n\u003ctd\u003eThin volume\u003c\/td\u003e\n\u003ctd\u003eFixed costs bite\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUrgent care facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUrgent care is a fast-growing but crowded market, with about 14,000 U.S. centers and more than 200 million visits a year. Surgery Partners, Inc. only has indirect exposure through ancillary services, so this is not a core leadership area for the business. To win share, it would need fresh capital, marketing, and tighter site expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutpatient total joint replacements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOutpatient total joint replacements are a high-growth question mark for Surgery Partners, Inc.; CMS added total knee arthroplasty to the ASC list in 2020 and total hip arthroplasty in 2021, which keeps more cases moving out of hospitals. If Surgery Partners, Inc. keeps winning surgeons and payer contracts, this can turn from a small base into a future star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotics-assisted surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRobotics-assisted surgery is a Question Mark for Surgery Partners, Inc. because it can draw surgeons and patients, but share is still being built in a market led by a few large platforms. New systems often cost about $1.5 million to $2.5 million, plus training and service spend, so adoption needs volume to pay off.\u003c\/p\u003e\n\u003cp\u003eThe category is growing, but the economic hurdle stays high. If Surgery Partners, Inc. converts more cases to robotic care, it can raise mix and referrals, yet it must prove it can win share without dragging margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew-state expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew-state expansion is a Question Mark for Surgery Partners, Inc.: it can drive growth, but each entry starts with low local share and a long ramp. The Company’s 31-state footprint shows the model can travel, yet every new market still needs capital, surgeons, and referral ties before it can scale. One clean fact: expansion is a launch point, not a moat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e31-state footprint supports market entry\u003c\/li\u003e\n\u003cli\u003eLow share at launch keeps returns uncertain\u003c\/li\u003e\n\u003cli\u003eNew sites need capital and physicians\u003c\/li\u003e\n\u003cli\u003eReferrals decide early market traction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based care partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValue-based care partnerships look like a question mark for Surgery Partners, Inc.: the model can grow as payers and surgeons push lower-cost settings, but market share is still early. Success hinges on tight contracting, better outcomes, and enough scale to spread fixed costs; Surgery Partners, Inc. reported $3.1 billion in 2024 revenue, showing room to convert volume into bundled and risk-based deals. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly share, but strong growth runway.\u003c\/li\u003e\n\u003cli\u003eBest if outcomes beat hospital costs.\u003c\/li\u003e\n\u003cli\u003eScale and contracts decide the winner.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgery Partners’ Growth Bets: High Upside, Still Proving Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Surgery Partners, Inc. are growth bets with low share today: urgent care, robotics, new-state entry, and value-based care. The upside is real, but each needs capital, surgeon pull, and payer wins. Surgery Partners, Inc. posted $3.1 billion revenue in 2024, yet these areas still need proof of scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotics\u003c\/td\u003e\n\u003ctd\u003e$1.5M-$2.5M per system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal joints\u003c\/td\u003e\n\u003ctd\u003eCMS-approved ASC growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew states\u003c\/td\u003e\n\u003ctd\u003e31-state footprint, low local share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based care\u003c\/td\u003e\n\u003ctd\u003eEarly share, scale needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234955665673,"sku":"sgry-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sgry-bcg-matrix.webp?v=1785731389","url":"https:\/\/dcfanalyst.com\/products\/sgry-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}